Mr. Altig has been a director since 2012. He is the Chief Financial Officer of Biotix Holdings, a manufacturer of microbiological consumables. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corp. (subsequently Verenium Corp.), a public company developing specialized industrial enzymes. Previously, Mr. Altig was the Chief Financial Officer of Maxim Pharmaceuticals, a public biopharmaceutical company. In addition, Mr. Altig serves as a director and Chairman of the audit committee for TearLab Corp. (formerly OccuLogix,) a publicly-traded eyecare technology company. He formerly was a director of MultiCell Technologies and Optimer Pharmaceuticals, which was a public company until its acquisition by Cubist Pharmaceuticals. Mr. Altig holds a BBA in Business from the University of Hawaii and is a certified public accountant.